Article Figures & Data
Figures
- FIGURE 1.
18F-FDOPA uptake in gliomas.
- FIGURE 2.
18F-FDOPA uptake and tumor grade in newly diagnosed and previously treated tumors combined (A), in newly diagnosed tumors (B), and in previously treated tumors (C).
- FIGURE 3.
Correlation between 18F-FDOPA uptake and Ki-67 index in newly diagnosed and previously treated tumors combined (A), in newly diagnosed tumors (B), and in previously treated tumors (C).
Tables
Characteristic All patients (n = 59) Newly diagnosed (n = 22) Recurrent (n = 37) Sex Female 19 (32) 9 (41) 10 (27) Male 40 (68) 13 (59) 27 (73) Age (y) Median 44.5 42.1 45.9 Range 23.1–71.2 23.9–64.3 23.1–71.2 Duration of disease (wk) Median 110.5 9.8 167.7 Range 0.1–984.69 0.1–33.4 3.9–984.9 Pathohistology WHO grade II 13 (22) 9 (41) 4 (11) Astrocytoma 4 (7) 4 (18) 0 Oligoastrocytoma 3 (5) 2 (9) 1 (3) Oligodendroglioma 6 (10) 3 (14) 3 (8) WHO grade III 19 (32) 7 (32) 12 (32) Anaplastic astrocytoma 8 (14) 2 (9) 6 (16) Anaplastic oligoastrocytoma 6 (10) 3 (14) 3 (8) Anaplastic oligodendroglioma 5 (8) 2 (9) 3 (8) WHO grade IV 27 (46) 6 (27) 21 (57) Glioblastoma 25 (42.4) 6 (27) 19 (51.4) Gliosarcoma 2 (3.4) 0 2 (5.4) Low-grade tumors 13 (22) 9 (41) 4 (11) High-grade tumors 43 (73) 13 (59) 33 (89) Astrocytomas 27 (46) 12 (55) 15 (41) Nonastrocytomas 32 (54) 10 (45) 22 (59) Data in parentheses are percentages.
Characteristic All patients (n = 59) Untreated (n = 22) Pretreated (n = 37) SUVmax ± SD 3.34 ± 1.38 3.45 ± 1.60 3.28 ± 1.26 Low grade WHO grade II 2.44 ± 1.26 2.34 ± 1.35 2.67 ± 1.18 WHO grade III 3.34 ± 1.02 3.38 ± 0.93 3.33 ± 1.10 WHO grade IV 3.78 ± 1.48 5.19 ± 0.93 3.38 ± 1.37 High grade 3.60 ± 1.32 4.22 ± 1.30 3.36 ± 1.26 WHO grade II vs. III P = 0.009 P = 0.044 P = 0.33 WHO grade II vs. IV P = 0.004 P = 0.007 P = 0.21 WHO grade III vs. IV P = 0.42 P = 0.010 P = 0.76 WHO grade II vs. III/VI P = 0.001 P = 0.005 P = 0.22 Mean Ki-67 index ± SD (%) 22.45 ± 20.69 17.32 ± 15.93 25.16 ± 22.59 WHO grade II 3.92 ± 2.36 3.44 ± 1.67 5.00 ± 3.56 WHO grade III 17.68 ± 9.06 19.29 ± 5.35 16.75 ± 10.78 WHO grade IV 35.19 ± 23.45 35.83 ± 16.25 33.81 ± 25.510 Tumors SUV index R P All (n = 59) Mean SUV 0.267 0.041 SUVmax 0.289 0.027 SUVmax20 0.310 0.017 Tumor burden 0.364 0.005 T/N mean SUV ratio 0.269 0.040 T/N SUVmax ratio 0.284 0.029 T/N SUVmax20 ratio 0.303 0.020 Newly diagnosed (n = 22) Mean SUV 0.647 0.001 SUVmax 0.656 0.001 SUVmax20 0.660 0.001 Tumor burden 0.666 0.001 T/N mean SUV ratio 0.779 <0.0001 T/N SUVmax ratio 0.778 <0.0001 T/N SUVmax20 ratio 0.786 <0.0001 Treated (n = 37) Mean SUV 0.113 0.51 SUVmax 0.140 0.41 SUVmax20 0.169 0.32 Tumor burden 0.269 0.11 T/N mean SUV ratio 0.024 0.89 T/N SUVmax ratio 0.060 0.72 T/N SUVmax20 ratio 0.085 0.62 SUVmax20 = mean values of voxels with top 20% SUVs; T/N ratio = ratio of 18F-FDOPA uptake to mean values of contralateral normal brain.
Tumor burden was obtained by multiplying tumor volume and mean SUV in volume.
Jump to section
Related Articles
Cited By...
- 18F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study
- O-(2-(18F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma
- Effects of L-DOPA Pretreatment on the Kinetics, Migration and Carbon Ion Radiation Response of T98G Cells
- The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma
- Comparison of the Amino Acid Tracers 18F-FET and 18F-DOPA in High-Grade Glioma Patients
- Clinical Impact of Amino Acid PET in Gliomas
- Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
- Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients
- Radiolabeled Amino Acids for Oncologic Imaging
- Correlation of MRI-Derived Apparent Diffusion Coefficients in Newly Diagnosed Gliomas with [18F]-Fluoro-L-Dopa PET: What Are We Really Measuring with Minimum ADC?
- Analysis of the Growth Dynamics of Angiogenesis-Dependent and -Independent Experimental Glioblastomas by Multimodal Small-Animal PET and MRI
- Impact of 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective
- Multimodality Assessment of Brain Tumors and Tumor Recurrence